tbuckley/cabot-search huggingface dataset:
Geographic Variation in Access to Cardiac Rehabilitation
Authors: Meredith S. Duncan, Natalie N. Robbins, Steven A. Wernke, Robert A. Greevy, Sandra L. Jackson, Alexis L. Beatty, Randal J. Thomas, Mary A. Whooley, Matthew S. Freiberg, Justin M. Bachmann
Journal: Journal of the American College of Cardiology (2023)
Risk of Sudden Death in Patients With RASopathy Hypertrophic Cardiomyopathy
Authors: Aine Lynch, Mark Tatangelo, Sachin Ahuja, Chun-Po Steve Fan, Sandar Min, Myriam Lafreniere-Roula, Tanya Papaz, Vivian Zhou, Kathryn Armstrong, Peter F. Aziz, Lee N. Benson, Ryan Butts, Andreea Dragulescu, Letizia Gardin, Justin Godown, Aamir Jeewa, Paul F. Kantor, Beth D. Kaufman, Ashwin K. Lal, John J. Parent, Marc Richmond, Mark W. Russell, Seshadri Balaji, Elizabeth A. Stephenson, Chet Villa, John L. Jefferies, Robert Whitehill, Jennifer Conway, Taylor S. Howard, Stephanie J. Nakano, Joseph Rossano, Robert G. Weintraub, Seema Mital
Journal: Journal of the American College of Cardiology (2023)

Genetic defects in the RAS/mitogen-activated protein kinase pathway are an important cause of hypertrophic cardiomyopathy (RAS-HCM). Unlike primary HCM (P-HCM), the risk of sudden cardiac death (SCD) and long-term survival in RAS-HCM are poorly understood.The study's objective was to compare transplant-free survival, incidence of SCD, and implantable cardioverter-defibrillator (ICD) use between RAS-HCM and P-HCM patients.In an international, 21-center cohort study, we analyzed phenotype-positive pediatric RAS-HCM (n = 188) and P-HCM (n = 567) patients. The between-group differences in cumulative incidence of all outcomes from first evaluation were compared using Gray's tests, and age-related hazard of all-cause mortality was determined.RAS-HCM patients had a lower median age at diagnosis compared to P-HCM (0.9 years [IQR: 0.2-5.0 years] vs 9.8 years [IQR: 2.0-13.9 years], respectively) (P < 0.001). The 10-year cumulative incidence of SCD from first evaluation was not different between RAS-HCM and P-HCM (4.7% vs 4.2%, respectively; P = 0.59). The 10-year cumulative incidence of nonarrhythmic deaths or transplant was higher in RAS-HCM compared with P-HCM (11.0% vs 5.4%, respectively; P = 0.011). The 10-year cumulative incidence of ICD insertions, however, was 5-fold lower in RAS-HCM compared with P-HCM (6.9% vs 36.6%; P < 0.001). Nonarrhythmic deaths occurred primarily in infancy and SCD primarily in adolescence.RAS-HCM was associated with a higher incidence of nonarrhythmic death or transplant but similar incidence of SCD as P-HCM. However, ICDs were used less frequently in RAS-HCM compared to P-HCM. In addition to monitoring for heart failure and timely consideration of advanced heart failure therapies, better risk stratification is needed to guide ICD practices in RAS-HCM.
Nonthrombogenic Roles of the Left Atrial Appendage
Authors: Mohamad Alkhouli, Luigi Di Biase, Andrea Natale, Charanjit S. Rihal, David R. Holmes, Samuel Asirvatham, Krzysztof Bartus, Dhanunjaya Lakkireddy, Paul A. Friedman
Journal: Journal of the American College of Cardiology (2023)
Cancer Risk in Patients With Congenital Heart Disease Exposed to Radiation From Cardiac Procedures
Authors: Andrea Borghini, Jonica Campolo, Giuseppe Annoni, Valentina Giuli, Rosa Sicari, Alessio Peretti, Antonella Mercuri, Eugenio Picano, Maria Grazia Andreassi
Journal: Journal of the American College of Cardiology (2023)
Corrigendum to “Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease” [J Hepatol 77 (2022) 918–930]
Authors: Katharina Staufer, Ursula Huber-Schönauer, Georg Strebinger, Philipp Pimingstorfer, Silke Suesse, Thomas-Matthias Scherzer, Bernhard Paulweber, Peter Ferenci, Thomas Stimpfl, Michel Yegles, Christian Datz, Michael Trauner
Journal: Journal of Hepatology (2023)
Corrigendum to: “Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆” [J Hepatol (2020) 505–515]
Authors: Quentin M. Anstee, Rebecca Darlay, Simon Cockell, Marica Meroni, Olivier Govaere, Dina Tiniakos, Alastair D. Burt, Pierre Bedossa, Jeremy Palmer, Yang-Lin Liu, Guruprasad P. Aithal, Michael Allison, Hannele Yki-Järvinen, Michele Vacca, Jean-Francois Dufour, Pietro Invernizzi, Daniele Prati, Mattias Ekstedt, Stergios Kechagias, Sven Francque, Salvatore Petta, Elisabetta Bugianesi, Karine Clement, Vlad Ratziu, Jörn M. Schattenberg, Luca Valenti, Christopher P. Day, Heather J. Cordell, Ann K. Daly
Journal: Journal of Hepatology (2023)
Mesocrystalline ZnS nanoparticles-augmented sonocatalytic full water splitting into H2/O2 for immunoactivating deep tumor
Authors: Chao Xia, Anbang Wu, Zhaokui Jin, Lingting Zeng, Lingdong Jiang, Qingqing Xu, Mingjian Fan, Qianjun He
Journal: Biomaterials (2023)
Extracorporeal membrane oxygenation in adults receiving haematopoietic cell transplantation: an international expert statement
Authors: Matteo Di Nardo, Graeme MacLaren, Peter Schellongowski, Elie Azoulay, Amy E DeZern, Cristina Gutierrez, Massimo Antonelli, Marta V Antonini, Gernot Beutel, Alain Combes, Rodrigo Diaz, Ibrahim Fawzy Hassan, Jo-Anne Fowles, In-Seok Jeong, Matthias Kochanek, Tobias Liebregts, Catherina Lueck, Karen Moody, Jessica A Moore, Laveena Munshi, Matthew Paden, Frédéric Pène, Kathryn Puxty, Matthieu Schmidt, Dawid Staudacher, Thomas Staudinger, Joachim Stemmler, R Scott Stephens, Lisa Vande Vusse, Philipp Wohlfarth, Roberto Lorusso, Antonio Amodeo, Kris M Mahadeo, Daniel Brodie
Journal: The Lancet Respiratory Medicine (2023)
Effectiveness of one dose of MVA–BN smallpox vaccine against mpox in England using the case-coverage method: an observational study
Authors: Marta Bertran, Nick Andrews, Chloe Davison, Bennet Dugbazah, Jacob Boateng, Rachel Lunt, Joanne Hardstaff, Melanie Green, Paula Blomquist, Charlie Turner, Hamish Mohammed, Rebecca Cordery, Sema Mandal, Colin Campbell, Shamez N Ladhani, Mary Ramsay, Gayatri Amirthalingam, Jamie Lopez Bernal
Journal: The Lancet Infectious Diseases (2023)
Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study
Authors: Samuel Lederman, Faith D Ottery, Antonio Cano, Nanette Santoro, Marla Shapiro, Petra Stute, Rebecca C Thurston, Marci English, Catherine Franklin, Misun Lee, Genevieve Neal-Perry
Journal: The Lancet (2023)
Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study
Authors: Celine Y Tan, Calvin J Chiew, Deanette Pang, Vernon J Lee, Benjamin Ong, David Chien Lye, Kelvin Bryan Tan
Journal: The Lancet Infectious Diseases (2023)
Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments
Authors: J. Ros, J. Matito, G. Villacampa, R. Comas, A. Garcia, G. Martini, I. Baraibar, N. Saoudi, F. Salvà, Á. Martin, M. Antista, R. Toledo, E. Martinelli, F. Pietrantonio, A. Boccaccino, C. Cremolini, R. Dienstmann, J. Tabernero, A. Vivancos, E. Elez
Journal: Annals of Oncology (2023)

Combination of a BRAF inhibitor (BRAFi) and an anti-epidermal growth factor receptor (EGFR), with or without a MEK inhibitor (MEKi), improves survival in BRAF-V600E-mutant metastatic colorectal cancer (mCRC) over standard chemotherapy. However, responses are heterogeneous and there are no available biomarkers to assess patient prognosis or guide doublet- or triplet-based regimens. In order to better characterize the clinical heterogeneity observed, we assessed the prognostic and predictive role of the plasmatic BRAF allele fraction (AF) for these combinations.
Development of treatment-decision algorithms for children evaluated for pulmonary tuberculosis: an individual participant data meta-analysis
Authors: Kenneth S Gunasekera, Olivier Marcy, Johanna Muñoz, Elisa Lopez-Varela, Moorine P Sekadde, Molly F Franke, Maryline Bonnet, Shakil Ahmed, Farhana Amanullah, Aliya Anwar, Orvalho Augusto, Rafaela Baroni Aurilio, Sayera Banu, Iraj Batool, Annemieke Brands, Kevin P Cain, Lucía Carratalá-Castro, Maxine Caws, Eleanor S Click, Lisa M Cranmer, Alberto L García-Basteiro, Anneke C Hesseling, Julie Huynh, Senjuti Kabir, Leonid Lecca, Anna Mandalakas, Farai Mavhunga, Aye Aye Myint, Kyaw Myo, Dorah Nampijja, Mark P Nicol, Patrick Orikiriza, Megan Palmer, Clemax Couto Sant'Anna, Sara Ahmed Siddiqui, Jonathan P Smith, Rinn Song, Nguyen Thuy Thuong Thuong, Vibol Ung, Marieke M van der Zalm, Sabine Verkuijl, Kerri Viney, Elisabetta G Walters, Joshua L Warren, Heather J Zar, Ben J Marais, Stephen M Graham, Thomas P A Debray, Ted Cohen, James A Seddon
Journal: The Lancet Child & Adolescent Health (2023)
It is time for ambitious, transformational change to the epidemic countermeasures ecosystem
Authors: Els Torreele, Christine McNab, Olusoji Adeyi, Roxana Bonnell, Mandeep Dhaliwal, Fatima Hassan, Michel Kazatchkine, Hani Kim, Jerome Kim, Helena Legido-Quigley, Joanne Liu, Sania Nishtar, Kiat Ruxrungtham, Petro Terblanche, Eloise Todd, Marcos da Silva Freire, Germán Velásquez, Ellen Johnson Sirleaf, Helen Clark
Journal: The Lancet (2023)
Complete resolution of gastric antral vascular ectasia after autologous haematopoietic stem cell transplantation in systemic sclerosis
Authors: Shiri Keret, Tsila Zuckerman, Israel Henig, Tova Rainis, Safwat Odeh, Naim Artoul, Aniela Shouval, Gleb Slobodin, Doron Rimar
Journal: Annals of the Rheumatic Diseases (2023)
Age-associated microenvironmental changes highlight the role of PDGF-C in ER+ breast cancer metastatic relapse
Authors: Frances K. Turrell, Rebecca Orha, Naomi J. Guppy, Andrea Gillespie, Matthew Guelbert, Chris Starling, Syed Haider, Clare M. Isacke
Journal: Nature Cancer (2023)

Abstract Patients with estrogen receptor (ER)-positive breast cancer are at risk of metastatic relapse for decades after primary tumor resection and treatment, a consequence of dormant disseminated tumor cells (DTCs) reawakening at secondary sites. Here we use syngeneic ER + mouse models in which DTCs display a dormant phenotype in young mice but accelerated metastatic outgrowth in an aged or fibrotic microenvironment. In young mice, low-level Pdgfc expression by ER + DTCs is required for their maintenance in secondary sites but is insufficient to support development of macrometastases. By contrast, the platelet-derived growth factor (PDGF)-C hi environment of aging or fibrotic lungs promotes DTC proliferation and upregulates tumor cell Pdgfc expression stimulating further stromal activation, events that can be blocked by pharmacological inhibition of PDGFRα or with a PDGF-C-blocking antibody. These results highlight the role of the changing microenvironment in regulating DTC outgrowth and the opportunity to target PDGF-C signaling to limit metastatic relapse in ER + breast cancer.
SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancers
Authors: Lei Shi, William Shen, Mindy I. Davis, Ke Kong, Phuong Vu, Supriya K. Saha, Ramzi Adil, Johannes Kreuzer, Regina Egan, Tobie D. Lee, Patricia Greninger, Jonathan H. Shrimp, Wei Zhao, Ting-Yu Wei, Mi Zhou, Jason Eccleston, Jonathan Sussman, Ujjawal Manocha, Vajira Weerasekara, Hiroshi Kondo, Vindhya Vijay, Meng-Ju Wu, Sara E. Kearney, Jeffrey Ho, Joseph McClanaghan, Ellen Murchie, Giovanna S. Crowther, Samarjit Patnaik, Matthew B. Boxer, Min Shen, David T. Ting, William Y. Kim, Ben Z. Stanger, Vikram Deshpande, Cristina R. Ferrone, Cyril H. Benes, Wilhelm Haas, Matthew D. Hall, Nabeel Bardeesy
Journal: Nature Cancer (2023)

Adult liver malignancies, including intrahepatic cholangiocarcinoma and hepatocellular carcinoma, are the second leading cause of cancer-related deaths worldwide. Most individuals are treated with either combination chemotherapy or immunotherapy, respectively, without specific biomarkers for selection. Here using high-throughput screens, proteomics and in vitro resistance models, we identify the small molecule YC-1 as selectively active against a defined subset of cell lines derived from both liver cancer types. We demonstrate that selectivity is determined by expression of the liver-resident cytosolic sulfotransferase enzyme SULT1A1, which sulfonates YC-1. Sulfonation stimulates covalent binding of YC-1 to lysine residues in protein targets, enriching for RNA-binding factors. Computational analysis defined a wider group of structurally related SULT1A1-activated small molecules with distinct target profiles, which together constitute an untapped small-molecule class. These studies provide a foundation for preclinical development of these agents and point to the broader potential of exploiting SULT1A1 activity for selective targeting strategies. Shi et al. report a sulfonation-dependent vulnerability of liver tumors expressing the sulfotransferase SULT1A1 by showing their sensitivity to the small molecule YC-1 and identifying structurally related compounds that can be modified by SULT1A1.
CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
Authors: Nicolas R. Barthélemy, Benjamin Saef, Yan Li, Brian A. Gordon, Yingxin He, Kanta Horie, Erik Stomrud, Gemma Salvadó, Shorena Janelidze, Chihiro Sato, Vitaliy Ovod, Rachel L. Henson, Anne M. Fagan, Tammie L. S. Benzinger, Chengjie Xiong, John C. Morris, Oskar Hansson, Randall J. Bateman, Suzanne E. Schindler
Journal: Nature Aging (2023)

Cerebrospinal fluid (CSF) amyloid-β peptide (Aβ)42/Aβ40 and the concentration of tau phosphorylated at site 181 (p-tau181) are well-established biomarkers of Alzheimer's disease (AD). The present study used mass spectrometry to measure concentrations of nine phosphorylated and five nonphosphorylated tau species and phosphorylation occupancies (percentage phosphorylated/nonphosphorylated) at ten sites. In the present study we show that, in 750 individuals with a median age of 71.2 years, CSF pT217/T217 predicted the presence of brain amyloid by positron emission tomography (PET) slightly better than Aβ42/Aβ40 (P = 0.02). Furthermore, for individuals with positive brain amyloid by PET (n = 263), CSF pT217/T217 was more strongly correlated with the amount of amyloid (Spearman's ρ = 0.69) than Aβ42/Aβ40 (ρ = -0.42, P < 0.0001). In two independent cohorts of participants with symptoms of AD dementia (n = 55 and n = 90), CSF pT217/T217 and pT205/T205 were better correlated with tau PET measures than CSF p-tau181 concentration. These findings suggest that CSF pT217/T217 and pT205/T205 represent improved CSF biomarkers of amyloid and tau pathology in AD.
Insufficient epitope-specific T cell clones are responsible for impaired cellular immunity to inactivated SARS-CoV-2 vaccine in older adults
Authors: Chanchan Xiao, Zhiyao Ren, Bei Zhang, Lipeng Mao, Guodong Zhu, Lijuan Gao, Jun Su, Jiezhou Ye, Ze Long, Yue Zhu, Pengfei Chen, Xiangmeng Su, Tong Zhou, Yanhao Huang, Xiongfei Chen, Chaojun Xie, Jun Yuan, Yutian Hu, Jingshan Zheng, Zhigang Wang, Jianrong Lou, Xiang Yang, Zhiqiang Kuang, Hongyi Zhang, Pengcheng Wang, Xiaofeng Liang, Oscar Junhong Luo, Guobing Chen
Journal: Nature Aging (2023)

Abstract Aging is a critical risk factor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine efficacy. The immune responses to inactivated vaccine for older adults, and the underlying mechanisms of potential differences to young adults, are still unclear. Here we show that neutralizing antibody production by older adults took a longer time to reach similar levels in young adults after inactivated SARS-CoV-2 vaccination. We screened SARS-CoV-2 variant strains for epitopes that stimulate specific CD8 T cell response, and older adults exhibited weaker CD8 T-cell-mediated responses to these epitopes. Comparison of lymphocyte transcriptomes from pre-vaccinated and post-vaccinated donors suggested that the older adults had impaired antigen processing and presentation capability. Single-cell sequencing revealed that older adults had less T cell clone expansion specific to SARS-CoV-2, likely due to inadequate immune receptor repertoire size and diversity. Our study provides mechanistic insights for weaker response to inactivated vaccine by older adults and suggests the need for further vaccination optimization for the old population.
Impact of selective reporting of antibiotic susceptibility testing results for urinary tract infections in the outpatient setting: a prospective controlled before-after intervention study
Authors: Maïa Simon, Sébastien Fougnot, Patrice De Monchy, Alain Duda, Nathalie Thilly, Céline Pulcini, Aurélie Bocquier, Alexandre Charmillon, Virginie Chopard, Marion Delpuech, Anne Fagot-Campagna, Joëlle Kivits, Gaëlle Le Dref, Alain Lozniewski, Amandine Luc, Violaine Mauffrey, Christian Rabaud, Emmanuelle Varon
Journal: Clinical Microbiology and Infection (2023)

The use of selective reporting of antibiotic susceptibility testing (AST) results is a recommended antimicrobial stewardship strategy to improve the appropriateness of antibiotic prescriptions. We conducted a large, pragmatic, prospective, multicentre, controlled (selective reporting versus complete reporting) before-after intervention study to assess the impact of selective reporting of AST results for Escherichia coli-positive urine cultures on the prescription of broad-spectrum antibiotics carrying a higher risk of selection of resistance (i.e. amoxicillin-clavulanate, third-generation cephalosporins, and quinolones) in the outpatient setting. We also looked for possible unintended clinical consequences of the intervention leading to consultations and/or hospitalizations.We compared two groups of laboratories located in a French region. We collected data from the health insurance databases before (2017) and after the implementation of the intervention (2019). The primary outcome was the prescription proportion of broad-spectrum antibiotics.We included 42,956 Escherichia coli-positive urine cultures with AST. The decrease in the proportion of broad-spectrum antibiotic prescriptions between 2017 and 2019 was significantly higher for selective reporting of AST, attributable to a decrease in the prescription proportion of third-generation cephalosporins (-8.5% for selective reporting versus -0.1% for complete reporting, p < 0.001). This impact was more marked for targeted therapy and female patients. Requests from clinicians for the complete reporting of AST results were infrequent (1.2% of all the selective AST results reported in 2019). No unintended consequences were observed.The results showed a positive impact of the selective reporting of AST results, but room for improvement is still important.
Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up
Authors: Noam Barda, Yaniv Lustig, Victoria Indenbaum, Daniel Zibly, Gili Joseph, Keren Asraf, Yael Weiss-Ottolenghi, Sharon Amit, Limor Kliker, Bayan Abd Elkader, Eytan Ben-Ami, Michal Canetti, Ravit Koren, Shiri Katz-Likvornik, Osnat Halpern, Ella Mendelson, Ram Doolman, Dror Harats, Yitshak Kreiss, Michal Mandelboim, Gili Regev-Yochay
Journal: Clinical Microbiology and Infection (2023)
Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants
Authors: Bin Ju, Qi Zhang, Ziyi Wang, Zhen Qin Aw, Peng Chen, Bing Zhou, Ruoke Wang, Xiangyang Ge, Qining Lv, Lin Cheng, Rui Zhang, Yi Hao Wong, Huixin Chen, Haiyan Wang, Sisi Shan, Xuejiao Liao, Xuanling Shi, Lei Liu, Justin Jang Hann Chu, Xinquan Wang, Zheng Zhang, Linqi Zhang
Journal: Nature Immunology (2023)

Abstract The omicron variants of SARS-CoV-2 have substantial ability to escape infection- and vaccine-elicited antibody immunity. Here, we investigated the extent of such escape in nine convalescent patients infected with the wild-type SARS-CoV-2 during the first wave of the pandemic. Among the total of 476 monoclonal antibodies (mAbs) isolated from peripheral memory B cells, we identified seven mAbs with broad neutralizing activity to all variants tested, including various omicron subvariants. Biochemical and structural analysis indicated the majority of these mAbs bound to the receptor-binding domain, mimicked the receptor ACE2 and were able to accommodate or inadvertently improve recognition of omicron substitutions. Passive delivery of representative antibodies protected K18-hACE2 mice from infection with omicron and beta SARS-CoV-2. A deeper understanding of how the memory B cells that produce these antibodies could be selectively boosted or recalled can augment antibody immunity against SARS-CoV-2 variants.
A single-amino acid substitution in the adaptor LAT accelerates TCR proofreading kinetics and alters T-cell selection, maintenance and function
Authors: Wan-Lin Lo, Miriam Kuhlmann, Gabrielle Rizzuto, H. Atakan Ekiz, Elizabeth M. Kolawole, Monica P. Revelo, Rakieb Andargachew, Zhongmei Li, Yuan-Li Tsai, Alexander Marson, Brian D. Evavold, Dietmar Zehn, Arthur Weiss
Journal: Nature Immunology (2023)

Abstract Mature T cells must discriminate between brief interactions with self-peptides and prolonged binding to agonists. The kinetic proofreading model posits that certain T-cell antigen receptor signaling nodes serve as molecular timers to facilitate such discrimination. However, the physiological significance of this regulatory mechanism and the pathological consequences of disrupting it are unknown. Here we report that accelerating the normally slow phosphorylation of the linker for activation of T cells (LAT) residue Y136 by introducing an adjacent Gly135Asp alteration (LAT G135D ) disrupts ligand discrimination in vivo. The enhanced self-reactivity of LAT G135D T cells triggers excessive thymic negative selection and promotes T-cell anergy. During Listeria infection, LAT G135D T cells expand more than wild-type counterparts in response to very weak stimuli but display an imbalance between effector and memory responses. Moreover, despite their enhanced engagement of central and peripheral tolerance mechanisms, mice bearing LAT G135D show features associated with autoimmunity and immunopathology. Our data reveal the importance of kinetic proofreading in balancing tolerance and immunity.
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
Authors: Christoph K. Stein-Thoeringer, Neeraj Y. Saini, Eli Zamir, Viktoria Blumenberg, Maria-Luisa Schubert, Uria Mor, Matthias A. Fante, Sabine Schmidt, Eiko Hayase, Tomo Hayase, Roman Rohrbach, Chia-Chi Chang, Lauren McDaniel, Ivonne Flores, Rogier Gaiser, Matthias Edinger, Daniel Wolff, Martin Heidenreich, Paolo Strati, Ranjit Nair, Dai Chihara, Luis E. Fayad, Sairah Ahmed, Swaminathan P. Iyer, Raphael E. Steiner, Preetesh Jain, Loretta J. Nastoupil, Jason Westin, Reetakshi Arora, Michael L. Wang, Joel Turner, Meghan Menges, Melanie Hidalgo-Vargas, Kayla Reid, Peter Dreger, Anita Schmitt, Carsten Müller-Tidow, Frederick L. Locke, Marco L. Davila, Richard E. Champlin, Christopher R. Flowers, Elizabeth J. Shpall, Hendrik Poeck, Sattva S. Neelapu, Michael Schmitt, Marion Subklewe, Michael D. Jain, Robert R. Jenq, Eran Elinav
Journal: Nature Medicine (2023)